EFPIA

How to deal with the main principles governing transparency and anti-kickback? A conference hosted by Fieldfisher in partnership with Pharmaceutiques.

EFPIA represents direct membership of 33 national associations and 40 leading pharmaceutical companies; collectively EFPIA provides the voice of 1,900 companies. With the benefit of hindsight and detailed figures courtesy of qordata EU Compliance AnalyticsTM 3, we can begin to draw three key insights : 1. With the total spend of Euro 2022 billion on medicines across EU in 2017, the relative percentage of spend on HCPs and HCOs by pharmaceutical manufacturers is small. The big five countries (France, UK, Germany, Italy and Spain) collectively spent around €1.9 billion in 2015 and €2 billion in 2016, or around 1% of …

Drugmakers in the U.K. led by AstraZeneca Plc increased payments to local health-care organizations, doctors and other workers by 25 percent last year,with most of that money going toward research and development, voluntary disclosures by the recipients showed. The spending climbed to 455 million pounds ($590 million) last year, according to a report on Friday from the Association of the British Pharmaceutical Industry, which collects the data. Cambridge-based AstraZeneca had the highest expenditure, at 56 million pounds, said Karen Borrer, head of reputation at the lobbying group. Almost two-thirds of health-care workers consented to sharing details of payments and benefits, up from about 55 …

PHILIPPE, Roi des Belges, A tous, présents et à venir, Salut. Vu l’article 108 de la Constitution; Vu la loi du 18 décembre 2016 portant des dispositions diverses en matière de santé, articles 42, § 1er, alinéa 2, et § 2, alinéa 2, 43, § 1er, alinéa 5, et 48, §§ 1er et 2; Vu les avis de l’Inspection des Finances, donnés le 21 février 2017 et le 26 avril 2017; Vu les avis n° 61.113/2 et n° 61.458/2 du Conseil d’Etat, respectivement donnés le 5 avril 2017 et le 29 mai 2017, en application de l’article 84, § 1er, …

For organizations with a multi-market presence, the relationship between Data, Analytics and Transparency can be a complex one. Using Analytics For Business/Compliance Monitoring At Roche, Italy In this webinar, the presenters describe the various ways such organizations can use Transparency Data, and how that subsequently directs evolution in their Business Direction/Model. Presenters will also draw from Roche Italy’s own experiences in showing the advantages of using Transparency Data, the various forms of Compliance and the benefits of Substantial Compliance. Click here for further information.

On 27 December 2016, the Belgian Law of 18 December 2016 concerning various health-related matters (“the Sunshine Act “) was adopted by the Belgian Ministry for Public Health. The Sunshine Act introduces several substantial changes to the current Belgian legal and regulatory framework for medicinal products and medical devices. The transparency obligation laid down in the Sunshine Act applies to all entities engaged in an economic activity, regardless of their legal status and the way in which they are financed. The obligation applies: to marketing authorisation holders for medicinal products for human or veterinary use; to importers, manufacturers and distributors …